The company now expects its annual 2024 revenue to grow between 20% and 21%, up from its previous forecast of 16% to 19% ...
Insulet (Nasdaq:PODD) shares ticked up today on third-quarter results that came in well ahead of the consensus forecast.
On Wednesday, Novo Nordisk A/S (NYSE:NVO) reported third-quarter 2024 sales of 71.311 billion Danish kroner (around $10.3 ...
Tandem Diabetes Care shares ticked up after hours today on third-quarter results that topped the consensus forecast.
Drugs Ozempic and Wegovy have slimmed down Hollywood stars — and millions of non-celebrities worldwide— while adding great ...
Novo Nordisk AS (NVO) reports strong financial performance with a 24% sales increase, driven by demand for diabetes and ...
Tandem Diabetes Care (TNDM) and Insulet (PODD) stocks draw outperform ratings at Bernstein as insulin pump makers prepare for ...
C Midwest Express Clinic. Discover five practical tips that you can incorporate into your day-to-day routine to help prevent ...
So what is semaglutide and who uses it in India? Semaglutide belongs to the class of drugs called Glucagon-like peptide-1 ...
Investor's Business Daily on MSN2d
Insulet Soars Out Of Buy Zone As 'Beat-And-Raise Cadence' ContinuesInsulet stock soared out of a buy zone Friday after the insulin pump-maker "continued the beat-and-raise cadence it has seen in 2024." ...
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, ...
13d
ThinkEquity is acting as sole placement agent for the offering.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback